[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641127":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":37,"responsibleParty":54,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":26,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calcitonin group","EXPERIMENTAL","patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks.",[13],"Drug: Calcitonin",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","patients will receive subcutaneous saline (1 ml) daily for three weeks.",[19],"Other: Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Calcitonin","patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks",[9],null,{"type":6,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Saline",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Amira M Elkeblawy, MD","CONTACT","01148529429","002","marmoramero999@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Tanta University Hospitals","RECRUITING","Tanta","Gharbia Governorate","31527","Egypt","EG",{"type":47,"coordinates":48},"Point",[49,50],31.00192,30.78847,{"lat":50,"lon":49},[53],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Amira Elkabalawy","Assistant professor of anesthesiology, surgical intensive care and pain medicine Tanta university","100641127","phase-3-subcutaneous-calcitonin-in-acute-herpes-zoster-100641127",false,"NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.","ALL","50 Years",{"count":68,"type":69},168,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[23,75,76],"Subcutaneous","Acute Herpes Zoster","2026-07-01",{"date":79,"type":80},"2026-07-06","ACTUAL",{"date":77,"type":80},{"date":83,"type":69},"2027-10-01",{"name":5,"class":6},1]